Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tyrothricin** is a naturally derived topical polypeptide antibiotic complex produced by *Brevibacillus brevis*. It comprises gramicidin peptides and tyrocidine cyclic peptides. Its antimicrobial activity is principally mediated by direct interaction with microbial cytoplasmic membranes, causing pore formation, disturbed membrane organization and permeability, ion leakage, and loss of essential cellular functions. Because of local and systemic toxicity risk, tyrothricin is used as a local anti-infective rather than a systemic antibiotic, including in products for superficial bacterial wound infections and local oropharyngeal infections. A Phase IIa study has evaluated tyrothricin-containing Tyrosur gel in an experimental wound-healing model. ([engelhard.de](https://www.engelhard.de/en/therapeutic-applications-and-products/skin-diseases/tyrosur))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tyrothricin.